Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is a fast-growing global medical concern, affecting approximately one-third of the population, with numbers rising. Recognized as a multisystemic disease, MASLD extends beyond the liver, presenting extrahepatic manifestations such as cardiovascular disease, type 2 diabetes, endocrine disorders such as hypothyroidism and polycystic ovarian syndrome, chronic kidney disease, psoriasis, and extrahepatic malignancies. This review aims to summarize the systemic effects of MASLD/NAFLD and to highlight possible shared pathophysiological pathways, including insulin resistance, lipid metabolism dysregulation, inflammation, oxidative stress, and gut dysbiosis. In addition, we discuss emerging therapeutic strategies for MASLD/NAFLD and its associated comorbidities. By integrating current evidence, this review provides insights into the multisystemic nature of MASLD and underscores the need for comprehensive management approaches.

Keywords

MASLD / NAFLD / cardiovascular disease / multisystem / cardiometabolic

References

[1] Kim GA,Kim W.Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced modernity.Clin Mol Hepatol2023;29:831-43 PMCID:PMC10577343

[2] Eslam M,Wong VW.The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Hepatol Int2020;14:889-919

[3] van Kleef LA,Brouwer WP.Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.JHEP Rep2021;3:100350 PMCID:PMC8446794

[4] Wang X.Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis.J Clin Transl Hepatol2022;10:128-33 PMCID:PMC8845159

[5] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. PMCID:PMC10653297

[6] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[7] Kim D,Wijarnpreecha K,Loomba R.Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.Clin Mol Hepatol2025;31:382-93 PMCID:PMC12016658

[8] Kim D,Wijarnpreecha K,Ahmed A.Trends in mortality from chronic liver disease before, during, and after the COVID-19 pandemic, 2015 to 2023.Ann Intern Med2025;178:1054-7

[9] Kim D,Wijarnpreecha K,Ahmed A.Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States.Clin Mol Hepatol2025;31:e268-72 PMCID:PMC12260643

[10] Sohn W, Lee YS, Kim SS, et al; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025. Clin Mol Hepatol. 2025;31:S1-31. PMCID:PMC11925433

[11] Charlton MR,Pedersen RA,Heimbach JK.Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.Gastroenterology2011;141:1249-53

[12] Koh JH, Ng CH, Nah B, Tan DJH, Loomba R, Huang DQ; Nash HCC Transplant Collaborative. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2024;22:197-9.e3. PMCID:PMC10939135

[13] Kim D,Wijarnpreecha K,Ahmed A.Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018-2023.Clin Mol Hepatol2024;30:756-70 PMCID:PMC11540356

[14] Le P,Dasarathy S.Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050.JAMA Netw Open2025;8:e2454707 PMCID:PMC11742522

[15] Younossi ZM,Blissett R.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Hepatology2016;64:1577-86

[16] Baumeister SE,Marschall P.Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.Gastroenterology2008;134:85-94

[17] Konyn P,Kim D.Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.Clin Mol Hepatol2023;29:S43-57 PMCID:PMC10029952

[18] Danpanichkul P,Prasitsumrit V,Wijarnpreecha K.Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations.Clin Mol Hepatol2025;31:74-89 PMCID:PMC11791619

[19] Lindén D,Loomba R.Targeting PNPLA3 to treat MASH and MASH related fibrosis and cirrhosis.Liver Int2025;45:e16186 PMCID:PMC11907219

[20] Luo F,Das A.TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease.Hepatol Commun2022;6:448-60 PMCID:PMC8870032

[21] Varadharajan V,Massey WJ.Membrane-bound O-acyltransferase 7 (MBOAT7) shapes lysosomal lipid homeostasis and function to control alcohol-associated liver injury.Elife2024;12:RP92243 PMCID:PMC11034944

[22] Mahmood S,Thompson D.Hydroxysteroid 17β-dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high-fat diet obese mice.Exp Physiol2025;110:1071-86 PMCID:PMC12314643

[23] Hagström H,Ekstedt M.99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.J Hepatol2024;80:e76-7

[24] Targher G,Tilg H.NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.Gut2020;69:1691-705

[25] Hagström H,Ekstedt M.Cardiovascular risk factors in non-alcoholic fatty liver disease.Liver Int2019;39:197-204

[26] Masuoka HC.Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.Ann N Y Acad Sci2013;1281:106-22 PMCID:PMC3646408

[27] Saokaew S,Thawichai K.Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: a systematic review and meta-analysis.Medicine2021;100:e24557 PMCID:PMC7870191

[28] Simon TG,Hagström H,Ludvigsson JF.Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.Gut2022;71:1867-75

[29] Mantovani A,Csermely A.Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals.Gut2022;72:372-80

[30] Xu J,Zhang Y.Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events.Stroke2021;52:103-10

[31] Alon L,Raparelli V.Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.Eur J Prev Cardiol2022;29:938-46

[32] Abosheaishaa H,Ghallab M.Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: a systematic review and meta-analysis.Diabetes Metab Syndr2024;18:102938

[33] Gong H,Cheng F.Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis.J Int Med Res2021;49:3000605211047074 PMCID:PMC8489776

[34] Stahl EP,Lee SK,Chalasani NP.Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review.J Am Coll Cardiol2019;73:948-63

[35] Jiang F,Wang W,Yan Y.Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1.J Hepatol2020;72:156-66

[36] Badmus OO,Stec DE.Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease.Curr Hypertens Rep2023;25:151-62 PMCID:PMC10839567

[37] Chen X,Pang J.Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux.J Hepatol2023;79:1491-501

[38] Pezzino S,Castorina M,Latteri S.Role of perturbated hemostasis in MASLD and its correlation with adipokines.Life2024;14:93 PMCID:PMC10820028

[39] Chen Z,She Z,Li H.Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.Free Radic Biol Med2020;152:116-41

[40] Westcott F,Hodson L.Hepatic fatty acid and glucose handling in metabolic disease: potential impact on cardiovascular disease risk.Atherosclerosis2024;394:117237

[41] Deprince A,Staels B.Dysregulated lipid metabolism links NAFLD to cardiovascular disease.Mol Metab2020;42:101092 PMCID:PMC7600388

[42] Rinella ME,Siddiqui MS.AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.Hepatology2023;77:1797-835 PMCID:PMC10735173

[43] Cusi K,Barb D.American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD).Endocr Pract2022;28:528-62

[44] Mellemkjær A,Haldrup D,Thomsen KL.Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.Eur J Intern Med2024;122:28-34

[45] Correia LCL.Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts.N Engl J Med2018;379:1387

[46] Sofi F,Gensini GF.Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis.Am J Clin Nutr2010;92:1189-96

[47] Kawaguchi T,Kawaguchi A.Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials.Semin Liver Dis2021;41:225-34

[48] Haigh L,El Gendy K.The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis.Clin Nutr2022;41:1913-31

[49] Kim D,Cholankeril G.Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2021;19:1240-7.e5

[50] Tsunoda K,Kai Y,Uchida K.Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2021;54:1330-9

[51] van Kleef LA, Hofman A, Voortman T, de Knegt RJ. Objectively measured physical activity is inversely associated with nonalcoholic fatty liver disease: the rotterdam study.Am J Gastroenterol2022;117:311-8 PMCID:PMC8812433

[52] Franco I,Mirizzi A.Physical activity and low glycemic index Mediterranean diet: main and modification effects on NAFLD score. Results from a randomized clinical trial.Nutrients2020;13:66 PMCID:PMC7823843

[53] Abdelbasset WK,Kamel DM,Soliman GS.A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease.Medicine2019;98:e14918 PMCID:PMC6708753

[54] Wilding JPH,Calanna S.Once-weekly semaglutide in adults with overweight or obesity.N Engl J Med2021;384:989-1002

[55] Marso SP,Consoli A.Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.N Engl J Med2016;375:1834-44

[56] Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.

[57] Armstrong MJ,Aithal GP.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.Lancet2016;387:679-90

[58] Mantovani A,Targher G.Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.Lancet Gastroenterol Hepatol2022;7:367-78

[59] Majzoub AM,Barnard A.Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.Aliment Pharmacol Ther2021;54:880-9 PMCID:PMC8711247

[60] Francque SM, Bedossa P, Ratziu V, et al; NATIVE Study Group. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547-58.

[61] Thomson MJ,Khungar V.Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH study.Clin Gastroenterol Hepatol2022;20:458-60.e4 PMCID:PMC8464616

[62] Shahab O,Paik J,Golabi P.Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality.Hepatol Commun2018;2:1227-34 PMCID:PMC6167074

[63] Athyros VG, Tziomalos K, Gossios TD, et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916-22.

[64] Ayada I,Zhang H.Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study.EBioMedicine2023;87:104392 PMCID:PMC9758527

[65] Kaplan DE, Serper MA, Mehta R, et al; VOCAL Study Group. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology. 2019;156:1693-706.e12.

[66] Zhou X,Li L.Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis.Obes Surg2016;26:2590-601

[67] Kwok CS,Khan MA.Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis.Int J Cardiol2014;173:20-8

[68] Lassailly G,Ntandja-Wandji LC.Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis.Gastroenterology2020;159:1290-301.e5

[69] Sakai K,Toyokuni E.Metabolic dysfunction-associated steatotic liver disease: a superior predictor for incident type 2 diabetes over traditional criteria - NAGALA study.J Diabetes Investig2024;15:1788-96 PMCID:PMC11615691

[70] Mantovani A,Bonora E.Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis.Diabetes Care2018;41:372-82

[71] Björkström K,Hultcrantz R.Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol2017;15:1461-8

[72] Kim D,Ahmed A.Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023.Clin Mol Hepatol2025;31:e235-8 PMCID:PMC12260613

[73] Younossi ZM,de Avila L.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol2019;71:793-801

[74] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[75] Younossi ZM,Price JK.The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes.Clin Gastroenterol Hepatol2024;22:1999-2010.e8

[76] Ajmera V,Tesfai K.A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.J Hepatol2023;78:471-8 PMCID:PMC9975077

[77] Marušić M,Knobloch M.NAFLD, insulin resistance, and diabetes mellitus type 2.Can J Gastroenterol Hepatol2021;2021:6613827 PMCID:PMC7904371

[78] Sabatini S,Carli F.Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis.Cell Rep Med2024;5:101820 PMCID:PMC11604487

[79] Pal SC.Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis.World J Gastroenterol2023;29:3999-4008 PMCID:PMC10354585

[80] Zhang C,Liu S.Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Explor Dig Dis2023;2:246-75

[81] Yu L,Li Y.Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.Biomed Pharmacother2024;175:116724

[82] Ding Z,Peng J,Chen G.The potential role of C-reactive protein in metabolic-dysfunction-associated fatty liver disease and aging.Biomedicines2023;11:2711 PMCID:PMC10603830

[83] Boursier J,Barret M.The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.Hepatology2016;63:764-75 PMCID:PMC4975935

[84] Drummen M,Vreugdenhil ACE.Long-term effects of increased protein intake after weight loss on intrahepatic lipid content and implications for insulin sensitivity: a PREVIEW study.Am J Physiol Endocrinol Metab2018;315:E885-91

[85] Skytte MJ,Petersen AD.A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.Diabetologia2019;62:2066-78

[86] Cho Y-E,Seo W,Yoo S-H.Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress.Hepatology2021;73:2180-95 PMCID:PMC6783321

[87] Souza Cruz EM,Dalto da Rosa CVi.Long-term sucrose solution consumption causes metabolic alterations and affects hepatic oxidative stress in Wistar rats.Biol Open2020;9:bio047282 PMCID:PMC7055397

[88] Anania C,Olivero F,Chiesa C.Mediterranean diet and nonalcoholic fatty liver disease.World J Gastroenterol2018;24:2083-94 PMCID:PMC5960814

[89] Pinyopornpanish K,Pinyopornpanish K.Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels.Gut Liver2021;15:827-40 PMCID:PMC8593497

[90] Diabetes A. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2018.Diabetes Care2018;41:S73-85

[91] Lingvay I,Szczepaniak LS.Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes.J Diabetes Complications2007;21:137-42 PMCID:PMC1994788

[92] Cusi K,Bril F.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.Ann Intern Med2016;165:305-15

[93] Musso G,Paschetta E.Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis.JAMA Intern Med2017;177:633-40 PMCID:PMC5470366

[94] Ratziu V, Giral P, Jacqueminet S, et al; LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology. 2008;135:100-10.

[95] He Y,Yang J,Jin S.The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy.Ann Hepatol2020;19:44-52

[96] Bizino MB,de Heer P.Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.Diabetologia2020;63:65-74 PMCID:PMC6890592

[97] Eguchi Y, Kitajima Y, Hyogo H, et al; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45:269-78.

[98] Petit JM,Loffroy R.Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study.J Clin Endocrinol Metab2017;102:407-15

[99] Hartman ML,Loomba R.Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes.Diabetes Care2020;43:1352-5 PMCID:PMC7245348

[100] Gastaldelli A,Fernández Landó L,Brouwers B.Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol2022;10:393-406

[101] Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.

[102] Akuta N,Watanabe C.Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.Hepatol Res2019;49:531-9

[103] Seko Y,Tanaka S.Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.Hepatol Res2017;47:1072-8

[104] Gautam A,Doneria J.Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease.J Assoc Physicians India2018;66:62-6

[105] Lai L-L,Nik Mustapha NR,Chan W-K.Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus.Dig Dis Sci2020;65:623-31

[106] Kuchay MS,Mishra SK.Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial).Diabetes Care2018;41:1801-8

[107] Eriksson JW,Jansson PA.Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.Diabetologia2018;61:1923-34 PMCID:PMC6096619

[108] Shimizu M,Kato K.Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.Diabetes Obes Metab2019;21:285-92

[109] Bharatselvam S,Ghorbani Y.Assessing clinical and metabolic responses related to hyperlipidemia, MASLD and type 2 diabetes: sleeve versus RYGB.Nutrition2024;126:112530

[110] Wyne KL,Schneiderman CP.Hypothyroidism prevalence in the United States: a retrospective study combining national health and nutrition examination survey and claims data, 2009-2019.J Endocr Soc2022;7:bvac172 PMCID:PMC9706417

[111] Mantovani A,Bilson J.Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.Gut2024;73:1554-61

[112] Kim D,Escober JA.Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality.Am J Gastroenterol2020;115:1496-504

[113] Ritter MJ,Hollenberg AN.Thyroid hormone signaling and the liver.Hepatology2020;72:742-52

[114] Yan F,Lu M.Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.J Hepatol2014;61:1358-64

[115] Bao S,Duan L,Jiang X.Thyroid-stimulating hormone may participate in insulin resistance by activating toll-like receptor 4 in liver tissues of subclinical hypothyroid rats.Mol Biol Rep2023;50:10637-50

[116] Kizivat T,Mudri D,Primorac D.Hypothyroidism and nonalcoholic fatty liver disease: pathophysiological associations and therapeutic implications.J Clin Transl Hepatol2020;8:347-53 PMCID:PMC7562794

[117] Liu Y,Yu X.Thyroid function and risk of non-alcoholic fatty liver disease in euthyroid subjects.Ann Hepatol2018;17:779-88

[118] Liu L,Zhao M.Benefits of levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients.Int J Endocrinol2017;2017:5753039 PMCID:PMC5394912

[119] Harrison SA,Guy CD.Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet2019;394:2012-24

[120] Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.

[121] Manzano-Nunez R,Rivera-Esteban J.Non-alcoholic fatty liver disease in patients with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-regression.J Clin Med2023;12:856 PMCID:PMC9917911

[122] Shengir M,Guadagno E.Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: a systematic review and meta-analysis.JGH Open2021;5:434-45 PMCID:PMC8035436

[123] Kumarendran B,Manolopoulos KN.Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database.PLoS Med2018;15:e1002542 PMCID:PMC5873722

[124] Andrisse S,Ma Y.Low-dose dihydrotestosterone drives metabolic dysfunction via cytosolic and nuclear hepatic androgen receptor mechanisms.Endocrinology2017;158:531-44 PMCID:PMC5460775

[125] Zhang Y,Sun X.Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver.Oncotarget2018;9:18180-97 PMCID:PMC5915065

[126] Kelley CE,Diehl AM.Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.World J Gastroenterol2014;20:14172-84 PMCID:PMC4202347

[127] Witchel SF,Peña AS.Curtailing PCOS.Pediatr Res2020;87:353-61

[128] Naderpoor N,de Courten B,Moran LJ.Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.Hum Reprod Update2015;21:560-74

[129] Austregésilo de Athayde De Hollanda Morais B, Martins Prizão V, de Moura de Souza M, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications. 2024;38:108834.

[130] Chane E,Hadgu R.Assessment of liver function tests of women taking hormonal contraceptives at University of Gondar comprehensive specialized hospital and Family Guidance Association of Gondar (FGAE), 2022; a comparative cross-sectional study.PLoS One2023;18:e0289746 PMCID:PMC10434896

[131] Byrne CD.NAFLD as a driver of chronic kidney disease.J Hepatol2020;72:785-801

[132] Marcuccilli M.NAFLD and chronic kidney disease.Int J Mol Sci2016;17:562 PMCID:PMC4849018

[133] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2022;71:156-62

[134] Paik J,Younoszai Z,Trimble G.Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease.Liver Int2019;39:342-52

[135] Sun DQ,Wang TY.MAFLD and risk of CKD.Metabolism2021;115:154433

[136] Hashim A,Elzanaty A.Nonalcoholic fatty liver disease predicts acute kidney injury readmission in heart failure hospitalizations: a nationwide analysis.Curr Probl Cardiol2023;48:101816

[137] Bansal A.Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations.Kidney Int2025;108:194-200

[138] Zhen J,He M.The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.Front Endocrinol2023;14:1085041 PMCID:PMC9941174

[139] Castillo-Rodriguez E,Esteras R.Impact of altered intestinal microbiota on chronic kidney disease progression.Toxins2018;10:300 PMCID:PMC6070989

[140] Abbate M,Montemayor S.Energy expenditure improved risk factors associated with renal function loss in NAFLD and mets patients.Nutrients2021;13:629 PMCID:PMC7919687

[141] Truong E.The interplay between nonalcoholic fatty liver disease and kidney disease.Clin Liver Dis2022;26:213-27

[142] Sumida Y,Toyoda H.Common drug pipelines for the treatment of diabetic nephropathy and hepatopathy: can we kill two birds with one stone?.Int J Mol Sci2020;21:4939 PMCID:PMC7404115

[143] Skov J,Frøkiær J.Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.J Clin Endocrinol Metab2013;98:E664-71

[144] Mima A.Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease.Adv Ther2021;38:2201-12

[145] Ruan Z,Chen Y.Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults.JAMA Dermatol2022;158:745-53 PMCID:PMC9134040

[146] Untaaveesup S,Ungprasert P.The risk of metabolic dysfunction-associated steatotic liver disease in moderate-to-severe psoriasis: a systematic review and meta-analysis.J Clin Med2025;14:1374 PMCID:PMC11855964

[147] Romero-Pérez D,Bellot P,Marco F.Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk.Australas J Dermatol2019;60:e304-10

[148] Mantovani A,Lonardo A.Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis?.Int J Mol Sci2016;17:217 PMCID:PMC4783949

[149] Costache DO,Cojocaru DL.Intersecting pathways: nonalcoholic fatty liver disease and psoriasis duet-A comprehensive review.Int J Mol Sci2024;25:2660 PMCID:PMC10932248

[150] Aryanian Z,Zanousi PP,Kebria AS.Adherence to the Mediterranean diet in patients with psoriasis and its relationship with the severity of the disease: a case-control study.Health Sci Rep2024;7:e70049 PMCID:PMC11410676

[151] Sualeheen A,Georgousopoulou E.Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease in non-Mediterranean, Western countries: What’s known and what’s needed?.Nutr Bull2024;49:444-62

[152] Gisondi P,Girolomoni G.Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis.J Eur Acad Dermatol Venereol2016;30:282-7

[153] Silva FS,Santos MS,Santos-Silva A.Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity.Toxicology2013;306:93-100

[154] Krefting F,Benson S.Baseline pathological liver function tests in patients with psoriasis support the indication for systemic therapy rather than being a reason against it: a real-world analysis.Psoriasis2025;15:29-44 PMCID:PMC11881625

[155] Jia X,Lu N,Xie C.Obstructive sleep apnea is ralated to metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus.Sci Rep2025;15:24627 PMCID:PMC12241494

[156] Aron-Wisnewsky J,Pépin JL.Nonalcoholic fatty liver disease and obstructive sleep apnea.Metabolism2016;65:1124-35

[157] Miao L,Guo LS.Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease.J Clin Transl Hepatol2022;10:230-7 PMCID:PMC9039714

[158] Feng T,Wu L,Ye J.Association between metabolic dysfunction-associated steatotic liver disease and pulmonary function: a population-based and two-sample mendelian randomization study.BMC Pulm Med2024;24:368 PMCID:PMC11290208

[159] Abdelhameed F,Kite C.Gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): emerging pathogenic mechanisms and therapeutic implications.Livers2025;5:11

[160] Loomba R,Li W.Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease.Cell Metab2017;25:1054-62.e5 PMCID:PMC5502730

[161] Martínez-Domínguez SJ,Gargallo-Puyuelo CJ.Inflammatory bowel disease is an independent risk factor for metabolic dysfunction-associated steatotic liver disease in lean individuals.Inflamm Bowel Dis2024;30:1274-83 PMCID:PMC11291618

[162] Yao J,Ebrahimi F.Long-term risk of chronic liver disease in patients with celiac disease: a nationwide population-based, sibling-controlled cohort study.Lancet Reg Health Eur2025;50:101201 PMCID:PMC11910788

[163] Wu S,Yang Z.Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study.BMC Med2022;20:262 PMCID:PMC9394037

[164] Sartini A,Bianchini M.Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease.Cell Death Dis2018;9:87 PMCID:PMC5833704

[165] Wei Z.Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease.Front Immunol2024;15:1375654 PMCID:PMC11063260

[166] Ng JJJ,Siah KTH.Associations between irritable bowel syndrome and non-alcoholic fatty liver disease: a systematic review.World J Hepatol2023;15:925-38 PMCID:PMC10401413

[167] Lee HJ,Kim CO.Association between 10-year fracture probability and nonalcoholic fatty liver disease with or without sarcopenia in Korean men: a nationwide population-based cross-sectional study.Front Endocrinol2021;12:599339 PMCID:PMC8044878

[168] Han E,Kim YD.Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk.Am J Gastroenterol2020;115:584-95

[169] Li X,Sun Q.The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.Clin Nutr2024;43:2005-16

[170] Petta S,Di Marco V.Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2017;45:510-8

[171] Wong R.Sarcopenia and metabolic dysfunction associated steatotic liver disease: time to address both.World J Hepatol2024;16:871-7 PMCID:PMC11212657

[172] Stefan N,Birkenfeld AL,White MF.The role of hepatokines in NAFLD.Cell Metab2023;35:236-52 PMCID:PMC10157895

[173] Kim MJ,Kim EH.Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography.J Cachexia Sarcopenia Muscle2024;15:1942-52 PMCID:PMC11446687

[174] Zhou BG,She Q.Association of MASLD with the risk of extrahepatic cancers: a systematic review and meta-analysis of 18 cohort studies.Eur J Clin Invest2024;54:e14276

[175] Kim GA,Choe J.Association between non-alcoholic fatty liver disease and cancer incidence rate.J Hepatol2017;68:140-6

[176] Allen AM,Mara KC,Therneau TM.The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study.J Hepatol2019;71:1229-36 PMCID:PMC6921701

[177] Kim D,Yoo ER.Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017.Gastroenterology2019;157:1055-66.e11

[178] Gallagher EJ.Hyperinsulinaemia in cancer.Nat Rev Cancer2020;20:629-44

[179] Zhang AMY,Kopp JL.Hyperinsulinemia in obesity, inflammation, and cancer.Diabetes Metab J2021;45:622 PMCID:PMC8369215

[180] Tilg H,Adolph TE.The intestinal microbiota fuelling metabolic inflammation.Nat Rev Immunol2020;20:40-54

[181] Cani PD.Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer.Nat Rev Gastroenterol Hepatol2018;15:671-82

[182] Tai J,Chen WT.Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype.Cancer Sci2024;115:564-74 PMCID:PMC10859614

[183] Longo M,Paolini E.TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models.Cell Mol Gastroenterol Hepatol2022;13:759-88 PMCID:PMC8783129

[184] Medina-Julio D,Cordova-Gallardo J,Cantú-Brito C.From liver to brain: how MAFLD/MASLD impacts cognitive function.Med Sci Monit2024;30:e943417 PMCID:PMC10836032

[185] Zolin A,Ooi H,Kamel H.Association of liver fibrosis with cognitive decline in Parkinson’s disease.J Clin Neurosci2024;119:10-6 PMCID:PMC11198872